Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, et al.
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21.
https://doi.org/10.1530/EJE-22-0689
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Margaret C S Boguszewski, Cesar L Boguszewski , et al.
Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52.
https://doi.org/10.1530/EJE-21-1186
Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop
John P Bilezikian 1, Aliya A Khan, et al.
J Bone Miner Res. 2022 Nov;37(11):2293-2314.
https://doi.org/10.1002/jbmr.4677
Genetics of Cushing’s disease: from the lab to clinical practice
Marily Theodoropoulou , Martin Reincke
Pituitary. 2022 Oct;25(5):689-692.
https://doi.org/10.1007/s11102-022-01253-9
Tumor-induced Osteomalacia: A Comprehensive Review
Salvatore Minisola , Seiji Fukumoto, et al.
Endocr Rev. 2023 Mar 4;44(2):323-353.
https://doi.org/10.1210/endrev/bnac026
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies
Antonio Marcondes Lerario, Dipika R Mohan, Gary D Hammer, et al.
Endocr Rev. 2022 Nov 25;43(6):1051-1073.
https://doi.org/10.1210/endrev/bnac012
Comentarios recientes